Baiyunshan: Subsidiary's Xuhan Ting Granules Approved for New Clinical Trial in Children with Recurrent Respiratory Tract Infections

LightningPacketLoss

2026-03-17 04:19:25

Abstract generation in progress

Recently, Baiyunshan announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., has received approval for a clinical trial of a new indication for Xuhanting Granules.

Xuhanting Granules are used to benefit qi and nourish yin, stabilize the exterior, and stop sweating. They are indicated for spontaneous sweating and night sweats caused by deficiency of qi and yin, as well as for children with night sweats. This product is an already marketed traditional Chinese medicine compound preparation. The current application is for a clinical trial to add use for children with recurrent respiratory infections.

As of the date of this announcement, Qixing Pharmaceutical has invested approximately 20.52 million yuan in research and development for Xuhanting Granules. In 2024, Qixing Pharmaceutical’s sales of Xuhanting Granules reached 49.09 million yuan.

(Baiyunshan Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.